Activity of Pazopanib and Trabectedin in Advanced Alveolar Soft Part Sarcoma

BACKGROUND. Alveolar soft part sarcoma (ASPS) is an exceedingly rare and orphan disease, without active drugs approved in the front line. Pazopanib and trabectedin are licensed for sarcoma treatment from second‐line, but very little and contradictory data are available on their activity in ASPS. Lac...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Oncologist
Main Authors: Stacchiotti, Silvia, Mir, Olivier, Le Cesne, Axel, Vincenzi, Bruno, Fedenko, Alexander, Maki, Robert G., Somaiah, Neeta, Patel, Shreyaskumar, Brahmi, Mehedi, Blay, Jean Y., Boye, Kjetil, Sundby Hall, Kirsten, Gelderblom, Hans, Hindi, Nadia, Martin‐Broto, Javier, Kosela, Hanna, Rutkowski, Piotr, Italiano, Antoine, Duffaud, Florence, Kobayashi, Eisuke, Casali, Paolo G., Provenzano, Salvatore, Kawai, Akira
Formato: Artigo
Idioma:Inglês
Publicado em: AlphaMed Press 2017
Assuntos:
Sarcomas
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5759809/
https://ncbi.nlm.nih.gov/pubmed/28754721
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2017-0161
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados